These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38255991)

  • 21. Optimization and evaluation of resveratrol amorphous solid dispersions with a novel polymeric system.
    Han G; Wang B; Jia M; Ding S; Qiu W; Mi Y; Mi Z; Qin Y; Zhu W; Liu X; Li W
    Math Biosci Eng; 2022 May; 19(8):8019-8034. PubMed ID: 35801455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
    Ikeda Y; Ozono I; Tajima S; Imao M; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
    PLoS One; 2014; 9(2):e89355. PubMed ID: 24586712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling.
    Zhang J; Hu W; Ding C; Yao G; Zhao H; Wu S
    Toxicol Lett; 2019 Oct; 313():50-59. PubMed ID: 31238089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanosponge for Iron Chelation and Efflux: A Ferroptosis-Inhibiting Approach for Myocardial Infarction Therapy.
    Lv Q; Lin J; Huang H; Ma B; Li W; Chen J; Wang M; Wang X; Fu G; Xiao Y
    Adv Sci (Weinh); 2024 Jul; 11(25):e2305895. PubMed ID: 38671590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.
    Rassu G; Soddu E; Cossu M; Brundu A; Cerri G; Marchetti N; Ferraro L; Regan RF; Giunchedi P; Gavini E; Dalpiaz A
    J Control Release; 2015 Mar; 201():68-77. PubMed ID: 25620068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desferrioxamine in warm reperfusion media decreases liver injury aggravated by cold storage.
    Arthur PG; Niu XW; Huang WH; Deboer B; Lai CT; Rossi E; Joseph J; Jeffrey GP
    World J Gastroenterol; 2013 Feb; 19(5):673-81. PubMed ID: 23429835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
    Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
    J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering.
    Yao Q; Liu Y; Selvaratnam B; Koodali RT; Sun H
    J Control Release; 2018 Jun; 279():69-78. PubMed ID: 29649529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
    Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
    Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
    Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
    Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
    Brodie C; Siriwardana G; Lucas J; Schleicher R; Terada N; Szepesi A; Gelfand E; Seligman P
    Cancer Res; 1993 Sep; 53(17):3968-75. PubMed ID: 8358725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboxymethyl chitosan nanoparticles loaded with bioactive peptide OH-CATH30 benefit nonscar wound healing.
    Sun T; Zhan B; Zhang W; Qin D; Xia G; Zhang H; Peng M; Li SA; Zhang Y; Gao Y; Lee WH
    Int J Nanomedicine; 2018; 13():5771-5786. PubMed ID: 30310280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferoxamine stimulates LDLR expression and LDL uptake in HepG2 cells.
    Guillemot J; Asselin MC; Susan-Resiga D; Essalmani R; Seidah NG
    Mol Nutr Food Res; 2016 Mar; 60(3):600-8. PubMed ID: 26577249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of iron chelating agent on Schistosoma mansoni infected murine model.
    Abdelgelil NH; Abdellatif MZM; Abdel-Hafeez EH; Belal US; Mohamed RM; Abdel-Razik AH; Hassanin KMA; Abdel-Wahab A
    Biomed Pharmacother; 2019 Jan; 109():28-38. PubMed ID: 30391706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.
    Breuer W; Ronson A; Slotki IN; Abramov A; Hershko C; Cabantchik ZI
    Blood; 2000 May; 95(9):2975-82. PubMed ID: 10779448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.